{"transactions":[{"id":1389166,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-10-08T20:44:02.000Z","date":"2024-10-07","kind":"sale","planned":false,"acquired":false,"shares":76920,"price":0.563,"value":43305.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5291 to $0.6038, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":388026,"source":{"system":"sec-edgar","filing":"0001628280-24-042541","document":"wk-form4_1728420235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024042541/wk-form4_1728420235.xml","form_type":"4"}},{"id":1389165,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-10-08T20:44:02.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":230645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition."}],"balance_after":464946,"source":{"system":"sec-edgar","filing":"0001628280-24-042541","document":"wk-form4_1728420235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024042541/wk-form4_1728420235.xml","form_type":"4"}},{"id":1583719,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-03-11T21:20:25.000Z","date":"2024-03-11","kind":"sale","planned":false,"acquired":false,"shares":14235,"price":0.8818,"value":12552.423,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.863 to $0.9112, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."}],"balance_after":234301,"source":{"system":"sec-edgar","filing":"0001628280-24-010281","document":"wk-form4_1710192010.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024010281/wk-form4_1710192010.xml","form_type":"4"}},{"id":1637696,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Appreciation Right","published_at":"2024-02-16T22:08:51.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":428248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date."}],"balance_after":428248,"derivative":{"exercise_price":0.921,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":428248},"source":{"system":"sec-edgar","filing":"0001628280-24-005379","document":"wk-form4_1708121312.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024005379/wk-form4_1708121312.xml","form_type":"4"}},{"id":1648828,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-02-12T22:23:28.000Z","date":"2024-02-12","kind":"sale","planned":false,"acquired":false,"shares":787,"price":1.0072,"value":792.6664,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.98 to $1.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."}],"balance_after":248536,"source":{"system":"sec-edgar","filing":"0001628280-24-004287","document":"wk-form4_1707776584.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024004287/wk-form4_1707776584.xml","form_type":"4"}},{"id":1749418,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-11-03T20:39:14.000Z","date":"2023-11-01","kind":"sale","planned":true,"acquired":false,"shares":67695,"price":0.73,"value":49417.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6841 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award"}],"balance_after":249323,"source":{"system":"sec-edgar","filing":"0001628280-23-036755","document":"wk-form4_1699043942.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023036755/wk-form4_1699043942.xml","form_type":"4"}},{"id":1751077,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-11-02T20:59:02.000Z","date":"2023-10-31","kind":"grant","planned":false,"acquired":true,"shares":230645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor."}],"balance_after":317018,"source":{"system":"sec-edgar","filing":"0001628280-23-036463","document":"wk-form4_1698958731.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023036463/wk-form4_1698958731.xml","form_type":"4"}},{"id":1956428,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-13T20:48:46.000Z","date":"2023-03-10","kind":"sale","acquired":false,"shares":16806,"price":0.84,"value":14117.04,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.82 to $0.89, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 51,179 shares represent restricted stock units."}],"balance_after":86373,"source":{"system":"sec-edgar","filing":"0001628280-23-007721","document":"wf-form4_167874051295561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023007721/wf-form4_167874051295561.xml","form_type":"4"}},{"id":2013249,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-15T22:13:39.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":928,"price":0.93,"value":863.04,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.92 to $0.98, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 99,679 shares represent restricted stock units."}],"balance_after":103179,"source":{"system":"sec-edgar","filing":"0001628280-23-003759","document":"wf-form4_167649920502600.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023003759/wf-form4_167649920502600.xml","form_type":"4"}},{"id":2120920,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Appreciation Right","published_at":"2022-11-09T21:22:32.000Z","date":"2022-11-07","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of November 7, 2022, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date."}],"balance_after":1000000,"derivative":{"exercise_price":1.8,"expiration_date":"2032-11-07","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001628280-22-029260","document":"wf-form4_166802891805410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828022029260/wf-form4_166802891805410.xml","form_type":"4"}},{"id":2364633,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-03-01T21:09:48.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":97000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Of the shares of common stock reported, 102,357 shares represent unvested restricted stock units."}],"balance_after":104107,"source":{"system":"sec-edgar","filing":"0001628280-22-004499","document":"wf-form4_164616896122495.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828022004499/wf-form4_164616896122495.xml","form_type":"4"}},{"id":2397281,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-02-14T21:21:14.000Z","date":"2022-02-11","kind":"tax_withholding","acquired":false,"shares":928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"Shares withheld by X4 Pharmaceuticals Inc. to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Of the shares of common stock reported, 5,357 shares represent unvested restricted stock units."}],"balance_after":7107,"source":{"system":"sec-edgar","filing":"0001628280-22-002507","document":"wf-form4_164487363627920.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828022002507/wf-form4_164487363627920.xml","form_type":"4"}},{"id":2771708,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-03-25T21:07:11.000Z","date":"2021-03-24","kind":"grant","acquired":true,"shares":8035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 11, 2022, February 11, 2023 and February 11, 2024 subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents unvested restricted stock units."}],"balance_after":8035,"source":{"system":"sec-edgar","filing":"0001628280-21-005665","document":"wf-form4_161670641436695.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828021005665/wf-form4_161670641436695.xml","form_type":"4"}},{"id":2962499,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":86914,"kind":"person","name":"Taveras Arthur","position":1,"cik":"0001830901","reported_name":"Taveras Arthur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-12-01T22:28:54.000Z","date":"2020-11-30","kind":"grant","acquired":true,"shares":121150,"price":6.6,"value":799590.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject tot he option shall vest on November 30, 2021, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":121150,"derivative":{"exercise_price":6.6,"expiration_date":"2030-11-29","underlying":"Common Stock","underlying_shares":121150},"source":{"system":"sec-edgar","filing":"0001628280-20-016956","document":"wf-form4_160686171893552.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828020016956/wf-form4_160686171893552.xml","form_type":"4"}}]}